Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
This article was originally published in Pharmaceutical Approvals Monthly
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
You may also be interested in...
Early termination of a large outcomes study of Roche’s CETP inhibitor dalcetrapib raises doubts about others in the class. Some analysts speculate that Eli Lilly may opt not to continue with its evacetrapib, but the company says it remains committed.
Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.